Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
The biotech says it will discontinue a second trial but will still offer full analyses of the data.
